BridgeBio Pharma Inc vs Biogen Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Biogen Inc trades at $202.7 (market cap $30.13B). The key difference: Biogen Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BBIO | BIIB | |
|---|---|---|
Market Cap | $16.36B | $30.13B |
Sector | Health | Health |
52-Week High | $90.17 | $216.63 |
52-Week Low | $47.29 | $128.93 |
Enterprise Value | $18.14B | $37.20B |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →